北京中医药大学学报2024，Vol.47Issue(3)：429-439,11.DOI:10.3969/j.issn.1006-2157.2024.03.018
较高危骨髓增生异常综合征伴原始细胞增多患者的中医证候特征及早期死亡危险因素研究
Analysis of TCM syndrome characteristics and factors associated with early death in higher-risk patients with myelodysplastic syndromes with excess blasts
摘要
Abstract
Objective We aimed to investigate the TCM syndrome characteristics and risk factors of early death in higher-risk patients with myelodysplastic syndromes with excess blasts (HR-MDS-EB). Methods The data of 57 HR-MDS-EB patients in the hematology ward of Xiyuan Hospital, China Academy of Chinese Medical Sciences admitted between January 2013 and August 2020 were analyzed. Patients were divided into an early death group and a non-early death group according to the survival time. The basic information, clinical characteristics, specialized examination, complete blood cell counts and laboratory examination result for first diagnosis, TCM syndrome characteristics, and other data of patients were collected and analyzed to screen the risk factors of death.Results There were statistically significant differences in Charlson comorbidity index (CCI) score, Barthel index score, platelet count at first diagnosis, blast ratio in peripheral blood, lactate dehydrogenase levels, blazing pathogenic heat pattern, and constipation between the early death group and the non-early death group (P<0.05). According to the result of the above univariate analysis, logistic multivariate regression analysis was performed for significant factors P<0.05. CCI score had statistically significant effects on the risk of death (P<0.05).Conclusion Higher CCI score is an independent risk factor for early death in HR-MDS-EB patients.关键词
骨髓增生异常综合征/死亡危险因素/原始细胞/查尔森合并症指数/中医证候特征/回顾性分析Key words
myelodysplastic syndromes/risk factors for death/blasts/Charlson comorbidity index score/TCM syndrome characteristics/retrospective analysis分类
医药卫生引用本文复制引用
张盛琪,蒋佩珍,高琰,刘青果,张朝畅,唐旭东..较高危骨髓增生异常综合征伴原始细胞增多患者的中医证候特征及早期死亡危险因素研究[J].北京中医药大学学报,2024,47(3):429-439,11.基金项目
国家自然科学基金面上项目(No.81673819,No.82074258) （No.81673819,No.82074258）
中国中医科学院科技创新工程重大攻关项目(No.CI2021A01701)National Natural Science Foundation of China(Nos.81673819,and 82074258) （No.CI2021A01701）
